DV281
Total Payments
$1.3M
Transactions
103
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $98,087 | 23 | 0 |
| 2019 | $891,360 | 58 | 0 |
| 2018 | $351,277 | 22 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 103 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC | Dynavax Technologies Corporation | $1.3M | 0 |
Top Doctors Receiving Payments for DV281
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Seattle, WA | $1.3M | 103 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.3M
- Total Doctors 0
- Transactions 103
About DV281
DV281 is a drug associated with $1.3M in payments to 0 healthcare providers, recorded across 103 transactions in the CMS Open Payments database. The primary manufacturer is Dynavax Technologies Corporation.
Payment data is available from 2018 to 2020. In 2020, $98,087 was paid across 23 transactions to 0 doctors.
The most common payment nature for DV281 is "Unspecified" ($1.3M, 100.0% of total).
DV281 is associated with 1 research study, including "Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC" ($1.3M).